Arkolith/Insider Trading/ALGS/Form 4

Nuechterlein Carole

Director, 10% OwnerAligos Therapeutics, Inc. (ALGS) · full profile →Form 4 · filed Oct 27, 2023
Net Buying
Open-Market Buys
$6.0M
Open-Market Sells
$0
Net Open-Market Flow
$6.0M
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 25, 2023Buy(P)7.9M$0.76$6.0M11.0M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 25, 2023Buy(P)4.0M$0.13$516K4.0M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-23-000320) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML